Harmony Biosciences Holdings, Inc. announced that new safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in patients with Prader-Willi syndrome (PWS) will be highlighted as a poster presentation during a late-breaking abstract session at the 37th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2023," in Indianapolis from June 3-7. Additional presentations by Harmony include an oral presentation covering a pooled analysis of clinically meaningful improvements in adults with narcolepsy, as well as poster presentations detailing the results of a pharmacokinetics study of WAKIX in breast milk and serum in healthy lactating women, and an ongoing prospective observational safety study evaluating WAKIX exposure in pregnant women and their offspring.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.62 USD | +1.61% | -1.04% | -5.33% |
Apr. 30 | Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise | MT |
Apr. 30 | Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.33% | 1.71B | |
+29.50% | 684B | |
+29.52% | 568B | |
-4.37% | 361B | |
+18.35% | 329B | |
+4.44% | 284B | |
+15.79% | 240B | |
+9.32% | 208B | |
-7.16% | 200B | |
+7.31% | 166B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. to Present New WAKIX Safety and Efficacy Data